+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030- Product Image
mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055092
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The mRNA Vaccines Market grew from USD 9.32 billion in 2024 to USD 10.40 billion in 2025. It is expected to continue growing at a CAGR of 11.86%, reaching USD 18.28 billion by 2030.

The mRNA vaccines market has rapidly emerged as one of the most dynamic and innovative sectors within the biotechnology and pharmaceutical industries. Advances in messenger RNA technology have spearheaded a paradigm shift in how diseases are prevented and treated, with researchers and companies working together to harness the potential of synthetic genetic materials. Recent breakthroughs have demonstrated the remarkable flexibility of mRNA vaccines in addressing a variety of health challenges, ranging from infectious diseases to complex chronic conditions. This introductory overview outlines the current state of mRNA technology, emphasizing its evolution from a novel concept to a cornerstone of modern therapeutics.

Over the past few years, the dynamic interplay between scientific innovation, technological refinement, and robust regulatory frameworks has enabled rapid market growth. The development of effective mRNA platforms is founded on decades of rigorous research and collaborative breakthroughs. As the global scientific community rallies behind the promise of mRNA vaccines, the market continues to expand its capacity to address both urgent health crises and long-term medical challenges.

The journey from laboratory bench to clinical application has not been without challenges, yet the inherent advantages of mRNA - its adaptability, speed of production, and potential for customization - present immense opportunities for further growth. Stakeholders, including academic researchers, healthcare providers, and policy decision-makers, have a vested interest in ensuring that this innovative platform reaches its full potential. The stage is set for an era of transformative change in global healthcare, driven by breakthroughs in mRNA vaccine technology.

Transformative Shifts in the mRNA Vaccine Landscape

The mRNA vaccine landscape has experienced transformative shifts that underscore the evolution of medical innovation and technological integration. In recent years, unprecedented advances in formulation techniques and delivery systems have redefined the boundaries of vaccine development. Enhanced methods in nucleoside modification, lipid nanoparticle encapsulation, and self-amplifying mRNA platforms mean that vaccines can be deployed more precisely and at greater speeds than previously imagined.

These transformative shifts are not limited solely to the technology itself; the regulatory environment, industrial collaborations, and public-private partnerships have advanced in tandem with scientific breakthroughs. A reformed regulatory outlook coupled with robust funding models has helped streamline clinical trials and expedite the approval process. Emerging trends indicate a movement away from traditional vaccine platforms toward more dynamic and responsive mRNA solutions that cater to rapidly changing health scenarios.

As a result, industry participants are better positioned to anticipate market needs and harness the potential of mRNA. The emphasis on scalability and adaptability is evident in the way manufacturers and innovators are rethinking production methodologies. By investing in innovative manufacturing processes and reimagining the vaccine life cycle, key players are not only responding to current challenges but are also preparing to meet future public health demands. This evolution is transforming market dynamics while setting a new standard for what is achievable with modern vaccine technology.

Key Segmentation Insights for mRNA Vaccine Market

A detailed analysis of the market reveals that segmentation plays a crucial role in understanding the diverse facets of the mRNA vaccine market. From the perspective of technology type, researchers evaluate platforms such as lipid nanoparticle platforms, naked mRNA technologies, nucleoside-modified mRNA technologies, and self-amplifying mRNA platforms. Within the naked mRNA category, focused examinations on peptide-based carriers and polymeric nanoparticles provide additional technical depth. When it comes to the route of administration, the study encompasses various delivery methods, including inhalable mRNA vaccines, injectable mRNA vaccines, and oral delivery systems.

Equally important is the manufacturing process, which is dissected across cell-free synthesis and in vitro transcription methods, each bearing implications on scalability and cost. Vaccine classification further divides the market into preventive vaccines and therapeutic vaccines, suggesting distinct development paths. The analysis also highlights application areas that extend from cardiovascular disorders and genetic disorders, where cystic fibrosis treatments and sickle cell disease mRNA approaches are investigated, to infectious diseases with a particular focus on COVID-19 vaccines and influenza mRNA vaccines, as well as oncology.

In addition, the segmentation considers the end-user spectrum, where biotechnology firms, contract research organizations, pharmaceutical companies, and research institutes play defining roles. The distribution channel aspect of the market is also a key consideration, with hospitals and retail pharmacies forming the basis of product delivery. This multilayered approach to segmentation provides a nuanced understanding of target areas, innovation drivers, and potential growth opportunities within the evolving mRNA vaccine market.

Based on Technology Type, market is studied across Lipid Nanoparticle (LNP) Platforms, Naked mRNA Technologies, Nucleoside-Modified mRNA Technologies, and Self-Amplifying mRNA Platforms. The Naked mRNA Technologies is further studied across Peptide-Based Carriers and Polymeric Nanoparticles.

Based on Route of Administration, market is studied across Inhalable mRNA Vaccines, Injectable mRNA Vaccines, and Oral Delivery System.

Based on Manufacturing Process, market is studied across Cell-Free Synthesis and In Vitro Transcription.

Based on Vaccine Classification, market is studied across Preventive Vaccines and Therapeutic Vaccines.

Based on Application Areas, market is studied across Cardiovascular Disorders, Genetic Disorders, Infectious Diseases, and Oncology. The Genetic Disorders is further studied across Cystic Fibrosis Treatments and Sickle Cell Disease mRNA Approaches. The Infectious Diseases is further studied across COVID-19 Vaccines and Influenza mRNA Vaccines.

Based on End-User, market is studied across Biotechnology Firms, Contract Research Organizations, Pharmaceutical Companies, and Research Institutes.

Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.

Global Regional Insights and Market Opportunities

The global reach of mRNA vaccine technology offers a range of regional insights that are especially pertinent in today’s connected world. In the Americas, strong investment in biotechnology research and development, coupled with robust healthcare infrastructure, has created fertile ground for mRNA innovations. North American markets, in particular, have been quick to adopt the latest vaccine technologies, leading to rapid integration into public health strategies.

Europe, Middle East & Africa showcase a mixed landscape where advanced healthcare systems in parts of Europe drive market maturity, while emerging markets in the Middle East and Africa offer significant potential through rapidly evolving regulatory frameworks and government incentives. These regions demonstrate a balanced blend of established research excellence and untapped market potential.

Meanwhile, the Asia-Pacific region stands out with its diverse market dynamics. The confluence of high population density, increasing bio-tech investments, and proactive government policies has fostered a thriving environment for mRNA vaccine development. The interplay between tradition and modernity in healthcare delivery, combined with improvements in regional manufacturing capacities, positions the Asia-Pacific as a vital market for future growth. These regional insights illustrate the broad geographic impact of mRNA vaccine innovation and underscore the importance of a tailored approach to market strategies in each region.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Company Performance Highlights and Competitive Landscape

A comprehensive look at the competitive landscape in the mRNA vaccine market reveals the active participation of several key industry players. Companies such as Acuitas Therapeutics Inc. and Arcturus Therapeutics Holdings Inc. have made significant inroads with their cutting-edge delivery platforms, while Alnylam Pharmaceuticals, Inc. has continued to push the boundaries of RNA-based therapies. AstraZeneca PLC and Bavarian Nordic AS represent established pharmaceutical giants with diverse therapeutic portfolios who have embraced mRNA technology with a strategic focus on innovation and scalability.

Biotechnology leaders including BioNTech SE and CureVac N.V. are pioneering new vaccine formulations and delivery systems, driving competitive benchmarks that resonate throughout the industry. Meanwhile, Chongqing Zhifei Biological Products Co.,Ltd. and Daiichi Sankyo Company, Limited underline the commitment of global players to mitigating public health challenges. Eli Lilly and Company and Ethris GmbH have leveraged their research expertise to develop mRNA platforms tailored for both preventive and therapeutic applications.

The landscape also features influential names such as GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., and Johnson & Johnson Services, Inc., whose substantial R&D investments have catalyzed market evolution. Merck & Co., Inc., Moderna Inc., Novartis AG, and Pfizer Inc. have each contributed significant breakthroughs in technology and market strategy, further intensifying the competitive race. Additional noteworthy companies include Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated. Their collective strategies, characterized by rigorous research and consistent market adaptation, underscore the strategic imperatives that define the mRNA vaccine landscape.

The report delves into recent significant developments in the mRNA Vaccines Market, highlighting leading vendors and their innovative profiles. These include Acuitas Therapeutics Inc., Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics Holdings Inc., AstraZeneca PLC, Bavarian Nordic AS, BioNTech SE, Chongqing Zhifei Biological Products Co.,Ltd., CureVac N.V., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Ethris GmbH, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated.

Strategic Recommendations for Market Advancement

Industry leaders are encouraged to prioritize adaptive strategies and proactive investments in advanced manufacturing techniques to maintain competitive advantage. It is imperative for decision-makers to anticipate regulatory trends and invest in agile production methods, such as cell-free synthesis and in vitro transcription, to reduce time-to-market for new vaccine candidates. Strengthening public-private partnerships can facilitate innovation and accelerate the development of next-generation mRNA platforms. Collaborative ventures that bridge research institutions and industry leaders will be essential to harness the full potential of mRNA technology.

Moreover, leveraging data-driven insights into market segmentation and regional dynamics can inform targeted product launch strategies. By closely monitoring end-user requirements and distribution channel efficiencies, market stakeholders can better navigate competitive pressures and ensure sustainable growth in a dynamic global landscape.

In summary, the current mRNA vaccine market is characterized by rapid technological advancements, multifaceted segmentation insights, and diverse regional opportunities. The evolution of this sector is driven by robust scientific innovation and evolving regulatory frameworks, which together enable scalable production and comprehensive market integration.

These concluding insights serve as a reminder that the future of healthcare is intricately tied to continuous adaptation, strategic foresight, and collaborative innovation. The journey ahead promises even greater opportunities as technological breakthroughs continue to reshape the market landscape.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of infectious diseases and emerging viral outbreaks spur demand for mRNA vaccines
5.1.1.2. Expansion of mRNA vaccine in animal health sectors is set to market potential
5.1.1.3. Public and governmental support for pandemic preparedness pushes forward mRNA vaccine initiatives
5.1.2. Restraints
5.1.2.1. Public skepticism towards new vaccine technologies, by misinformation, could impede uptake.
5.1.3. Opportunities
5.1.3.1. Developing educational campaigns and public-private partnerships to promote mRNA vaccine benefits and safety
5.1.3.2. Governmental and private funding to advance mRNA vaccine research and development
5.1.4. Challenges
5.1.4.1. Understanding the complex regulatory frameworks for mRNA vaccine approvals
5.2. Market Segmentation Analysis
5.2.1. Technology Type: Growing use of lipid nanoparticle platforms for their ability to deliver mRNA into cells effectively
5.2.2. Distribution Channel: Adoption of hospital pharmacies for storing and timely administering mRNA vaccines
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. mRNA Vaccines Market, by Technology Type
6.1. Introduction
6.2. Lipid Nanoparticle (LNP) Platforms
6.3. Naked mRNA Technologies
6.3.1. Peptide-Based Carriers
6.3.2. Polymeric Nanoparticles
6.4. Nucleoside-Modified mRNA Technologies
6.5. Self-Amplifying mRNA Platforms
7. mRNA Vaccines Market, by Route of Administration
7.1. Introduction
7.2. Inhalable mRNA Vaccines
7.3. Injectable mRNA Vaccines
7.4. Oral Delivery System
8. mRNA Vaccines Market, by Manufacturing Process
8.1. Introduction
8.2. Cell-Free Synthesis
8.3. In Vitro Transcription
9. mRNA Vaccines Market, by Vaccine Classification
9.1. Introduction
9.2. Preventive Vaccines
9.3. Therapeutic Vaccines
10. mRNA Vaccines Market, by Application Areas
10.1. Introduction
10.2. Cardiovascular Disorders
10.3. Genetic Disorders
10.3.1. Cystic Fibrosis Treatments
10.3.2. Sickle Cell Disease mRNA Approaches
10.4. Infectious Diseases
10.4.1. COVID-19 Vaccines
10.4.2. Influenza mRNA Vaccines
10.5. Oncology
11. mRNA Vaccines Market, by End-User
11.1. Introduction
11.2. Biotechnology Firms
11.3. Contract Research Organizations
11.4. Pharmaceutical Companies
11.5. Research Institutes
12. mRNA Vaccines Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Retail Pharmacies
13. Americas mRNA Vaccines Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific mRNA Vaccines Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa mRNA Vaccines Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Scenario Analysis
16.3.1. Pfizer and BioNTech secure FDA approval for tailored Omicron KP.2 COVID-19 vaccine
16.3.2. BioNTech and CEPI joined hands to enhance Africa's mRNA vaccine landscape with innovative research and local manufacturing
16.3.3. Moderna revealed late-stage trial advancements with progress in the evolution of mRNA vaccine technology
16.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. MRNA VACCINES MARKET MULTI-CURRENCY
FIGURE 2. MRNA VACCINES MARKET MULTI-LANGUAGE
FIGURE 3. MRNA VACCINES MARKET RESEARCH PROCESS
FIGURE 4. MRNA VACCINES MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL MRNA VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 11. GLOBAL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 13. GLOBAL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2030 (%)
FIGURE 15. GLOBAL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
FIGURE 17. GLOBAL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL MRNA VACCINES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 19. GLOBAL MRNA VACCINES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 21. GLOBAL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. AMERICAS MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES MRNA VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 25. UNITED STATES MRNA VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 30. MRNA VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 31. MRNA VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MRNA VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MRNA VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. MRNA VACCINES MARKET DYNAMICS
TABLE 7. GLOBAL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MRNA VACCINES MARKET SIZE, BY LIPID NANOPARTICLE (LNP) PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MRNA VACCINES MARKET SIZE, BY PEPTIDE-BASED CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MRNA VACCINES MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MRNA VACCINES MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MRNA VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MRNA VACCINES MARKET SIZE, BY INHALABLE MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MRNA VACCINES MARKET SIZE, BY INJECTABLE MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MRNA VACCINES MARKET SIZE, BY ORAL DELIVERY SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MRNA VACCINES MARKET SIZE, BY CELL-FREE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MRNA VACCINES MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MRNA VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MRNA VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MRNA VACCINES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MRNA VACCINES MARKET SIZE, BY CYSTIC FIBROSIS TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MRNA VACCINES MARKET SIZE, BY SICKLE CELL DISEASE MRNA APPROACHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MRNA VACCINES MARKET SIZE, BY COVID-19 VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MRNA VACCINES MARKET SIZE, BY INFLUENZA MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MRNA VACCINES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MRNA VACCINES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MRNA VACCINES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MRNA VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MRNA VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MRNA VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MRNA VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. CANADA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 76. CANADA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 77. CANADA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 79. CANADA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 81. CANADA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 82. CANADA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 83. CANADA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. CANADA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. MEXICO MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 86. MEXICO MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 87. MEXICO MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. MEXICO MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 90. MEXICO MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 93. MEXICO MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. MEXICO MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES MRNA VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. CHINA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 128. CHINA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 129. CHINA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. CHINA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 131. CHINA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 132. CHINA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 133. CHINA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 134. CHINA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 135. CHINA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. CHINA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. INDIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 138. INDIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 139. INDIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. INDIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 141. INDIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 142. INDIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 143. INDIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 144. INDIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 145. INDIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. INDIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. JAPAN MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 158. JAPAN MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 159. JAPAN MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. JAPAN MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 161. JAPAN MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 162. JAPAN MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 163. JAPAN MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 164. JAPAN MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 165. JAPAN MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. JAPAN MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. THAILAND MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 218. THAILAND MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 219. THAILAND MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. THAILAND MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 221. THAILAND MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 222. THAILAND MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 223. THAILAND MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 224. THAILAND MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 225. THAILAND MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. THAILAND MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 248. DENMARK MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 249. DENMARK MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 250. DENMARK MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. DENMARK MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 252. DENMARK MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 253. DENMARK MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 256. DENMARK MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. DENMARK MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. EGYPT MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 259. EGYPT MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 260. EGYPT MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. EGYPT MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 262. EGYPT MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 263. EGYPT MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 264. EGYPT MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 265. EGYPT MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 266. EGYPT MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. EGYPT MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. FINLAND MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 269. FINLAND MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 270. FINLAND MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. FINLAND MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 272. FINLAND MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 273. FINLAND MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 274. FINLAND MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 275. FINLAND MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 276. FINLAND MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. FINLAND MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. FRANCE MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 279. FRANCE MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 280. FRANCE MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. FRANCE MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 282. FRANCE MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 283. FRANCE MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 284. FRANCE MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 285. FRANCE MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 286. FRANCE MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 287. FRANCE MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. GERMANY MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 289. GERMANY MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 290. GERMANY MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. GERMANY MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 292. GERMANY MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 293. GERMANY MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 294. GERMANY MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 295. GERMANY MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 296. GERMANY MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 297. GERMANY MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. ITALY MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 309. ITALY MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 310. ITALY MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 311. ITALY MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 312. ITALY MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 313. ITALY MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 314. ITALY MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 315. ITALY MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 316. ITALY MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 317. ITALY MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. NETHERLANDS MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 319. NETHERLANDS MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 320. NETHERLANDS MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 321. NETHERLANDS MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. NIGERIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 329. NIGERIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 333. NIGERIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 334. NIGERIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 338. NORWAY MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 339. NORWAY MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 340. NORWAY MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 341. NORWAY MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 342. NORWAY MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 343. NORWAY MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 344. NORWAY MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 345. NORWAY MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 346. NORWAY MRNA VACCINES MARKET SIZ

Companies Mentioned

  • Acuitas Therapeutics Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • AstraZeneca PLC
  • Bavarian Nordic AS
  • BioNTech SE
  • Chongqing Zhifei Biological Products Co.,Ltd.
  • CureVac N.V.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Ethris GmbH
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.28 Billion
Compound Annual Growth Rate11.8%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

mRNA Platform - Global Strategic Business Report - Product Image

mRNA Platform - Global Strategic Business Report

  • Report
  • 334 Pages
  • Global
From
mRNA Platform Market by mRNA Type, mRNA Molecule, Application, Indication, End-User - Global Forecast 2025-2030 - Product Image

mRNA Platform Market by mRNA Type, mRNA Molecule, Application, Indication, End-User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
mRNA Vaccine and Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

mRNA Vaccine and Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
mRNA Vaccines and Therapeutics Market Report by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2024-2032 - Product Image

mRNA Vaccines and Therapeutics Market Report by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2024-2032

  • Report
  • 137 Pages
  • Global
From
mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035: Distribution by Application Area, Target Disease Indication and Geographical Regions - Product Image

mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035: Distribution by Application Area, Target Disease Indication and Geographical Regions

  • Report
  • 343 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.